Report Company Directory

AGILON HEALTH INC

• Join us at 10am EST for Barclays Weekly Healthcare Call: Key Catalysts & Events to Close 2024 | Friday, 06 December 2024 by Barclays
• Register Now for Barclays' Last Weekly Healthcare Call of the Year by Barclays
• Join us at 10am EST - Barclays Weekly Healthcare Call: Examining the Stock Implications of Trump’s Cabinet Picks After Double-Digit Moves | Friday, 22 November 2024 by Barclays
• Reminder: Barclays Weekly Healthcare Call: Life After Double-Digit Moves by Barclays
• Barclays Healthcare: Life After Double-Digit Moves by Barclays
• Starting at 10am EST - Barclays Weekly Healthcare Call: Answering all the obesity questions | Friday, 08 November 2024 by Barclays
• agilon health, Inc.: 3Q24: Disappointing Results Lead to Big EBITDA Cut by Barclays
• U.S. Health Care Facilities & Managed Care: 2024 Election: Potential Red Wave Implications for Medicare and ACA by Barclays
• Join us at 10am EDT for the Barclays Weekly Healthcare Call: Healthcare Positioning Into the Election | Friday, 01 November 2024 by Barclays
• Register now for November: Barclays Weekly Healthcare Call by Barclays

Agilysys Inc.

• Presentation Slides: Technology, Media, and Communications 2026 Outlook and Top Stock Picks by William Blair
• Technology, Media, and Communications Outlook and Top Stock Recommendations for 2026 by William Blair
• William Blair’s 2026 Top Picks Discussions: December 8–12, 2025 by William Blair
• William Blair’s 2026 Top Picks Discussions: December 8–12, 2025 by William Blair
• William Blair’s 2026 Top Picks Discussions: December 8–12, 2025 by William Blair
• William Blair’s 2026 Top Picks Discussions: December 8–12, 2025 by William Blair
• Organic SaaS Acceleration Before Broader Marriott Rollout, Which Is Encouragingly Now Moving to Beta Phase by William Blair
• Restaurant and Hospitality Tech Third-Quarter Preview; Buying Opportunity for Group on Recent Weakness by William Blair
• Tracking Restaurant Engagement, Digital Trends, and Brand Affinity: September 2025 by William Blair
• Equity Research Rewind: Third Quarter 2025 by William Blair

Agilyx

• Agilyx (Buy): Recommendation and target price withdrawn by Carnegie Investment Bank AB (publ)
• Agilyx (Buy): Taking on the yellow jersey by Carnegie Investment Bank AB (publ)
• Agilyx (Buy, TP: NOK37.00) - CCC construction in focus by DnB Markets
• Agilyx (Buy, TP: NOK38.00) - Firming up its second CCC by DnB Markets
• Agilyx (Buy, TP: NOK40.00) - Progressing as planned by DnB Markets
• Agilyx - Initiation of coverage - Completing the plastics cycle by DnB Markets
• Agilyx - Commissioned Research: Flash Comment: First Cyclyx Circularity Centre FID reached, with approval to move forward to construction by Nordea
• Agilyx - Commissioned Research: Flash Comment: L9M revenue down y/y, but continued improvement in gross profit contribution and business model repositioning in place by Nordea
• Agilyx - Commissioned Research: Flash Comment: Preparing for a new phase of growth by Nordea
• Agilyx - Commissioned research: Flash Comment: Several key operational and organizational announcements released – key milestones for next steps by Nordea

AGIO PAPER & INDUSTRIES LTD

Agios Pharmaceuticals Inc.

• Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia by GlobeNewsWire
• Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease by GlobeNewsWire
• Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition by GlobeNewsWire
• Agios Reports Third Quarter 2025 Financial Results and Provides Business Update by GlobeNewsWire
• Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia by GlobeNewsWire
• Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET by GlobeNewsWire
• Agios Pharmaceuticals Inc: 1 director by SmartInsider
• Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia by GlobeNewsWire
• Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia by GlobeNewsWire
• Agios Reports Second Quarter 2025 Financial Results and Provides Business Update by GlobeNewsWire